The company has commenced the trial of ivaltinostat to treat metastatic pancreatic ductal adenocarcinoma. Credit: Nemes Laszlo / Shutterstock.com.

CG Pharmaceuticals has started the Phase II trial of ivaltinostat with the recommended Phase II dose (RP2D) for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).

The Safety Review Committee (SRC) has determined the RP2D of ivaltinostat (250mg/m²) after reviewing safety data from three cohorts with its increasing dose levels in combination with a fixed capecitabine dose.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study is open for subject enrolment, following a unanimous recommendation from the SRC.

In the Phase II study, patients with metastatic PDAC who exhibit no evidence of disease progression after treatment with FOLFIRINOX initially will be assigned to receive either capecitabine monotherapy or combination therapy.

Progression-free survival (PFS) is the primary endpoint of the trial.

CG Pharmaceuticals global strategic planning vice-president Dr Gene Cho said: “I am thrilled and honoured to share this important study milestone and witness the commencement of Phase II, with an enrolment target of 52 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We extend our heartfelt gratitude to our investigators, partners, and, most importantly, our patients for their invaluable participation in this critical study.”

Ivaltinostat is a new anticancer therapeutic candidate designed for inhibiting the enzymatic activity of histone deacetylase. It has been assessed for haematologic malignancies and solid tumours.

CG Pharmaceuticals, a wholly owned US subsidiary of CG Invites, is focused on the development of advanced therapies to treat patients with cancer.